Zimmermann Martine 4

What Happened
Martine Zimmermann, a director of Ligand Pharmaceuticals (LGND), received equity awards on June 5, 2026: two grants of restricted stock units (RSUs) totaling 3,774 RSUs (836 + 2,938) at $0 acquisition price. To cover the tax liability on the RSU settlement, 182 shares were withheld by the company at $237.00 per share, a withholding value of $43,134. The RSU grants were approved by the Board at the company's annual meeting.

Key Details

• Transaction date: June 5, 2026 (Form filed June 9, 2026). Filing appears timely (within the standard two business days).
• Grants: 836 RSUs and 2,938 RSUs granted (total 3,774 RSUs) — acquisition price $0 (non-cash awards).
• Tax withholding: 182 shares withheld at $237.00/share = $43,134 (disposition for tax payment).
• Vesting: RSUs fully vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant (per footnotes).
• Shares owned after the transaction: not disclosed in the provided filing excerpt.
• Transaction codes: A = Award/Grant, F = Tax withholding in connection with RSU settlement.

Context
These were board-approved RSU grants (non-cash awards) rather than open-market purchases or option exercises. The tax-withholding action (shares withheld) is a common administrative step when RSUs settle and does not necessarily indicate buying or selling intent.